$ONCT
Oncternal Therapeutics Inc

2021 Q1 Form 10-Q Financial Statement

#000156459021025109 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $748.0K $578.0K
YoY Change 29.41% 22.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.790M $2.630M
YoY Change 6.08% 182.8%
% of Gross Profit
Research & Development $0.00 $0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.707M $5.329M
YoY Change 25.86% 88.44%
Operating Profit -$5.959M -$4.751M
YoY Change 25.43% 101.48%
Interest Expense $10.00K $10.00K
YoY Change 0.0% -80.0%
% of Operating Profit
Other Income/Expense, Net $13.00K
YoY Change -79.69%
Pretax Income -$5.950M -$4.740M
YoY Change 25.53% 106.99%
Income Tax
% Of Pretax Income
Net Earnings -$5.948M -$4.738M
YoY Change 25.54% 106.54%
Net Earnings / Revenue -795.19% -819.72%
Basic Earnings Per Share
Diluted Earnings Per Share -$121.2K -$308.6K
COMMON SHARES
Basic Shares Outstanding 15.39M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $111.2M $16.00M
YoY Change 595.0% -24.53%
Cash & Equivalents $111.2M $16.02M
Short-Term Investments
Other Short-Term Assets $1.900M $500.0K
YoY Change 280.0% -61.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $113.1M $16.56M
YoY Change 582.81% -26.38%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $200.0K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $800.0K $1.047M
YoY Change -23.59%
Total Long-Term Assets $1.000M $1.201M
YoY Change -16.74% 1101.0%
TOTAL ASSETS
Total Short-Term Assets $113.1M $16.56M
Total Long-Term Assets $1.000M $1.201M
Total Assets $114.1M $17.77M
YoY Change 542.27% -21.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.900M $1.376M
YoY Change 38.08% 129.33%
Accrued Expenses $2.773M $2.778M
YoY Change -0.18% 131.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.700M $7.317M
YoY Change -22.1% 306.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $100.0K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $100.0K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.700M $7.317M
Total Long-Term Liabilities $0.00 $100.0K
Total Liabilities $5.800M $7.400M
YoY Change -21.62% 311.11%
SHAREHOLDERS EQUITY
Retained Earnings -$88.70M -$70.31M
YoY Change 26.16%
Common Stock $15.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $108.3M $10.40M
YoY Change
Total Liabilities & Shareholders Equity $114.1M $17.77M
YoY Change 542.27% -21.39%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$5.948M -$4.738M
YoY Change 25.54% 106.54%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$5.985M -$4.036M
YoY Change 48.29% 11.09%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 459.0K 4.000K
YoY Change 11375.0% 100.0%
NET CHANGE
Cash From Operating Activities -5.985M -4.036M
Cash From Investing Activities 0.000
Cash From Financing Activities 459.0K 4.000K
Net Change In Cash -5.526M -4.032M
YoY Change 37.05% 8.68%
FREE CASH FLOW
Cash From Operating Activities -$5.985M -$4.036M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 onct Class Of Warrant Weighted Average Remaining Contractual Term
ClassOfWarrantWeightedAverageRemainingContractualTerm
P4Y4M24D
CY2021Q1 onct Warrant Weighted Average Remaining Contractual Term Exercised
WarrantWeightedAverageRemainingContractualTermExercised
P4Y7M2D
CY2021Q1 onct Class Of Warrant Weighted Average Remaining Contractual Term
ClassOfWarrantWeightedAverageRemainingContractualTerm
P4Y0M26D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4M24D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M24D
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3913000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2794000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
6707000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5959000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
11000
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5948000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4738000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49094
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15355
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-5948000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-4738000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
838000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
399000
CY2021Q1 onct Noncash Lease Expense
NoncashLeaseExpense
40000
CY2020Q1 onct Noncash Lease Expense
NoncashLeaseExpense
36000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
609000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-90000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
749000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
336000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-267000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
455000
CY2021Q1 onct Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-40000
CY2020Q1 onct Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-36000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-748000
CY2020Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-578000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5985000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4036000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
358000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
101000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
459000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5526000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4032000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
116737000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20051000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111211000
CY2021Q1 onct Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
1836000
CY2020Q1 us-gaap Stock Issued1
StockIssued1
415000
CY2020Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
179000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
112951000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
358000
CY2021Q1 onct Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash
AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
101000
CY2021Q1 onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
3000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
838000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5948000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
108303000
CY2020Q1 onct Issuance Of Bonus Awards With Stock Option In Lieu Of Cash
IssuanceOfBonusAwardsWithStockOptionInLieuOfCash
415000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4738000
CY2021Q1 onct Accrued Clinical Trials
AccruedClinicalTrials
1100000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111200000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-88700000
CY2021Q1 us-gaap Deferred Revenue
DeferredRevenue
900000
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
1600000
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
32000
CY2021Q1 onct Accrued Clinical Trials
AccruedClinicalTrials
1138000
CY2020Q4 onct Accrued Clinical Trials
AccruedClinicalTrials
980000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
308000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
77000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2773000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3042000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
138000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
77000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
215000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
204000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
173000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5031841
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.25
CY2021Q1 onct Exercise Of Warrants
ExerciseOfWarrants
754255
CY2021Q1 onct Warrant Exercised Price Per Share
WarrantExercisedPricePerShare
2.57
CY2021Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4277586
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.42
CY2021Q1 onct Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice
62.48
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.899
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.894
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
838000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
399000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
12400000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2107625
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.08
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2127000
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.78
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
168750
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.47
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
88049
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.06
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3977826
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.46
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.006
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y7M6D
CY2021Q1 onct Common Stock Warrants Reserved For Future Issuance
CommonStockWarrantsReservedForFutureIssuance
4278000
CY2021Q1 onct Common Stock Options Issued And Outstanding For Future Issuance
CommonStockOptionsIssuedAndOutstandingForFutureIssuance
4069000
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10491000

Files In Submission

Name View Source Status
0001564590-21-025109-index-headers.html Edgar Link pending
0001564590-21-025109-index.html Edgar Link pending
0001564590-21-025109.txt Edgar Link pending
0001564590-21-025109-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gbhcmm0hydxa000001.jpg Edgar Link pending
gbhcmm0hydxa000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
onct-10q_20210331.htm Edgar Link pending
onct-10q_20210331_htm.xml Edgar Link completed
onct-20210331.xsd Edgar Link pending
onct-20210331_cal.xml Edgar Link unprocessable
onct-20210331_def.xml Edgar Link unprocessable
onct-20210331_lab.xml Edgar Link unprocessable
onct-20210331_pre.xml Edgar Link unprocessable
onct-ex101_249.htm Edgar Link pending
onct-ex102_247.htm Edgar Link pending
onct-ex103_248.htm Edgar Link pending
onct-ex311_8.htm Edgar Link pending
onct-ex312_9.htm Edgar Link pending
onct-ex321_7.htm Edgar Link pending
onct-ex322_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending